| |
Strategic Alliances
Research Partnerships/Collaborations
Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market
BIOCON - MYLAN: 2009
Biocon Limited announced that it has executed a definitive agreement with Mylan Inc. (Nasdaq: MYL) for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace. Through this partnership, Mylan and Biocon bring together highly complementary capabilities that will significantly advance their efforts to secure a leading position in the emerging generic biologics industry.
About Mylan Inc:
Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest – and highest quality – product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.
Biocon Limited and Amylin Pharmaceuticals Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
Program will Focus on the Potential Treatment of Diabetes
BIOCON - AMYLIN: 2009
Biocon, Limited (NSE: BIOCON) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin’s “phybrid” technology. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity.
About Amylin Pharmaceuticals:
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com
Syngene and DuPont Crop Protection Forge Alliance Partnership
SYNGENE - DuPONT CROP PROTECTION: 2009
Syngene International, a subsidiary of BIOCON Ltd, Indian biotechnology major, announced its agreement as alliance partner with DuPont Crop Protection. Syngene has been a preferred research service provider to DuPont Crop Protection primarily in the field of discovery chemistry and biology and will now provide integrated research services, through its "one box" model, covering a broad range of R&D technical capabilities to support DuPont's discovery pipeline.
About DuPont:
DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.
SYNGENE- BRISTOL-MYERS SQUIBB: 2009
Syngene International and Bristol-Myers Squibb (BMS) [a global biopharmaceutical company, headquartered in New York], announced the opening of a fully dedicated research and development facility for BMS in Biocon Park, Bangalore. Syngene and BMS entered into this research partnership for developing integrated drug discovery and development capabilities in 2007. Through this partnership, Syngene will provide research and development services for discovery and early drug development to BMS. The dedicated research facility developed by Syngene spreads across an area of 200,000 sq. ft. and has capacity to accommodate over 450 employees. Syngene is the preferred research service provider to BMS for providing drug discovery and development process from initial hit to lead optimization to early pharmaceutical development to clinical nomination in Phase I and Phase II clinical studies.
About BMS:
Bristol-Myers Squibb (BMS), having units worldwide, manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular diseases, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to “discover, develop and deliver innovative medicines that help patients prevail over serious diseases.”
Syngene and Endo Pharma Collaboration to Develop Anti-cancer Novel Therapeutic Molecules
SYNGENE- ENDO PHARMACEUTICALS: 2010
Syngene and Endo Pharmaceuticals, a US-based, specialty healthcare solutions company, has entered into a discovery and development collaboration to develop novel biological therapeutic molecules against cancer. Through this partnership, Syngene and Endo Pharmaceuticals hope to leverage their synergistic capabilities to develop novel therapeutic molecules for a robust cancer pipeline.
About Endo Pharmaceuticals:
Endo Pharmaceuticals, incorporated in 1997, is a specialty pharmaceutical company engaged in research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children or central precocious puberty (CPP).The company markets its branded pharmaceutical products to physicians for pain management, urology, endocrinology, oncology, neurology, surgery and primary care.
Strategic Co-development ventures
Partnership for the co-development of immunoconjugates for targeted immunotherapy of cancers and infectious diseases
BIOCON- IATRICa, 2008
Biocon Limited and IATRICa, Inc. announced a strategic partnership to co-develop an exclusive new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies will co-develop candidate products based upon IATRICa’s technology platform and Biocon’s proven expertise in drug development, biologics manufacturing, and clinical research.
About IATRICa Inc.:
IATRICa is a privately held biotechnology company engaged in the discovery and development of novel targeted immunoconjugates for prevention or treatment of cancer and infectious disorders. IATRICa is a start-up company formed in 2007 with technology developed at the Johns Hopkins University, Baltimore, Maryland, USA, and has exclusive licenses to the immunoconjugate technology invented by Johns Hopkins scientists and company founders, Dr. Atul Bedi and Dr. Rajani Ravi. The company is headquartered in Baltimore, Maryland, USA.
Partnership to Discover and Develop Therapeutic Antibodies
BIOCON-VACCINEX: 2004
Biocon and Vaccinex, Inc. have embarked on a broad, strategic partnership to discover and co-develop fully humanized antibodies focused on cancer, inflammation and autoimmune diseases. The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.
Progress: Currently, BVX-20 a monoclonal antibody (intended for use in the treatment of patients with relapsed or chemotherapy resistant follicular B-cell NHL and CD20 positive diffuse large B- cell NHL in combination with chemotherapy) has moved into preclinical stages.
Vaccinex is a privately held biotechnology company headquartered in Rochester, New York engaged in the discovery and development of novel therapeutic antibodies.
Partnership to Manufacture and Market Biopharmaceuticals in GCC Countries
BIOCON- NEOPHARMA: 2007
Biocon and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).
This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.
Marketing Alliances and commercialization
Biocon and Pfizer enter into Global Commercialization Agreement for commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products
BIOCON – PFIZER: 2010
Biocon Limited and Pfizer entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Biocon will remain responsible for the clinical development, manufacture and supply of these biosimilar Insulin products, as well as for regulatory activities to secure approval for these products in various geographies. This alliance enables Biocon to extend its insulin portfolio to have a worldwide presence.
Licensing agreement for G CSF in North America and the European Union & for the commercialisation of ABRAXANE in India
BIOCON-ABRAXIS: 2007
Biocon and Abraxis BioScience, Inc. have announced an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. Under the terms of the agreement, Biocon will receive an upfront licensing fee and, following approval in the licensed territories, royalties from Abraxis BioScience.
In addition, Biocon and Abraxis BioScience Inc., have also announced a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf countries. As part of this agreement, Abraxis will receive royalties from Biocon based on net sales of ABRAXANE in these countries.
Progress: Drug Controller General of India (DCGI) approval has been obtained to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer.
Commercial introduction of ABRAXANE® in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab™ platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer.
Exclusive Marketing License for BIOMAb EGFR® for Pakistan
BIOCON-FEROZSONS: 2007
Biocon has granted an exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR® in Pakistan. The successful debut made by BIOMAb EGFR® in the Indian market since mid-September, 2006, has evinced strong licensing interest for the proprietary cancer drug in the region. Biocon's decision to select Ferozsons Laboratories Limited as its exclusive licensee in Pakistan was based on the leadership position that the company enjoys in Oncology.
Ferozsons Laboratories Limited is the foremost national Oncology company in Pakistan.
Collaboration in Research and Research-Education
BIOCON-KAROLINSKA INSTITUTE: 2005
Biocon signed a Memorandum of Understanding (MoU) with the Karolinska Institute, Sweden to collaborate in research and research-education initiatives.
The agreement outlines the following areas of collaboration:
- Partnering in product development
- Joint PhD studies at Karolinska Institute
- Joint research programs between Karolinska Institute and Biocon
- Scientific symposia in India sponsored by Biocon in association with Karolinska Institute
Progress
- Joint Ph.D. programs are being conducted.
- In 2006, Madras Diabetes Research Foundation (MDRF)
and Karolinska Institute of Sweden organized a diabetes symposium. Biocon was a co-sponsor.
Karolinska Institute is Sweden's leading medical university, reputed to be among Europe's best. The institute's reputation for visionary science has afforded it the exceptional honour and responsibility to nominate The Nobel Prize for Medicine and Physiology every year.
Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management
BIOCON - ISB: 2009
Biocon Limited, India's pioneering biotechnology company and the Indian School of Business (ISB) have launched the Biocon Cell for Innovation Management (BCIM) to promote innovation in business. The Cell will be established under the aegis of the Centre for Leadership, Innovation, and Change (CLIC) at the ISB. BCIM at the ISB will help organizations find answers to questions such as the gaps in a company's ability to innovate, assessing the required understanding to manage and mitigate risks associated with innovation and how to produce high value, high quality, strategic innovation at low cost. Biocon is contributing an initial investment of Rs. 1 crore to set up BCIM.
About ISB:
The Indian School of Business is a premier management institution established in 2001. In a short span of seven years, the ISB has successfully pioneered several new trends in management education in India and has established itself as a leading B-school across the world. The ISB has a strong pool of research oriented resident faculty and invites high calibre international faculty from reputed B-schools to teach in its Post Graduate Programme in Management/Executive Education Programmes as well as to participate in collaborative research with the resident faculty. The ISB has academic associations with the Kellogg School of Management, The Wharton School, and the London Business School.
Partnership for Greater Focus in Biotechnology and Biosciences Research
BIOCON- DEAKIN UNIVERSITY: 2007
Biocon signed a Memorandum of Understanding with Deakin University for cooperation in the following areas:
-Establishment of the Deakin Research Institute in Bangalore.
-Joint development of a mammalian cell bio-processing
facility at Geelong, Victoria, Australia.
Deakin University, Victoria is Australia's fastest growing university in multi- disciplinary research with greater focus in biotechnology and biosciences research.
|
|
